• Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms 

      Janson, Eva Tiensuu; Knigge, Ulrich; Dam, Gitte; Federspiel, Birgitte; Grønbaek, Henning; Stålberg, Peter; Langer, Seppo W.; Kjaer, Andreas; Arola, Johanna; Schalin-Jäntti, Camilla; Sundin, Anders; Welin, Staffan; Thiis-Evensen, Espen; Sorbye, Halfdan (Journal article; Peer reviewed, 2021)
      Background The diagnostic work-up and treatment of patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) has undergone major advances and new methods are introduced. Furthermore, an update of the WHO ...
    • Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms 

      Morken, Siren; Langer, Seppo W.; Sundlöv, Anna; Vestermark, Lene Weber; Ladekarl, Morten; Hjortland, Geir Olav; Svensson, Johanna B.; Tabaksblat, Elizaveta Mitkina; Haslerud, Torjan Magne; Assmus, Jörg; Detlefsen, Sönke; Couvelard, Anne; Perren, Aurel; Sorbye, Halfdan (Journal article; Peer reviewed, 2023)
      Background The optimal treatment for metastatic high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms when Ki-67 ≤55% is unknown. A prospective multi-centre phase 2 study was performed to evaluate the efficacy ...